Ostertag Eric 4

4 · Poseida Therapeutics, Inc. · Filed Oct 13, 2021

Form 4

Period: 2021-10-11

DirectorChief Executive Officer10% Owner

Transactions

Exercise/Conversion
Common Stock
2021-10-11$9.15/sh+18,525$169,504→ 696,422 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-10-11−18,525→ 740,995 total
Exercise: $9.15Exp: 2031-02-03→ Common Stock (18,525 underlying)

Holdings

Footnotes (7)

[F1]Includes 2,482 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2021.
[F2]The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
[F3]The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
[F4]The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
[F5]The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
[F6]The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
[F7]12.5% of the shares originally subject to the stock option vested and became exercisable on August 4, 2021, and the remaining shares vest in 42 equal monthly installments thereafter.

Documents

1 file